Chimeric antigen receptor -engineered T cell therapy (CAR-T) is the most promising approach for cancer treatment, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies. A 2nd or 3rd generation CAR (Chimeric antigen receptor) mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region, a costimulatory molecule such as CD28, and an internal signaling domain such as CD3ζ.

In order to meet your specified CAR-T cell production, we can provide a variety of high-titer recombinant virus packaging services from experimental design to vector packaging, production, purification, quality verification and other clinical and scientific research applications. Lentiviruses are widely used in scientific research and clinics because of their high infection efficiency for mammalian cells, and are one of the common viruses used to construct CAR-T cells. However, lentivirus infection of primary T cells is always a challenging task, especially for T cells in a resting state, lentivirus infection efficiency is usually less than 10%, which undoubtedly increases the difficulty of CAR-T cell construction.
 

Our lentiviral packaging team has been engaged in lentivirus-related work for a long time, in terms of increasing the ability of lentivirus to carry foreign genes, improving lentivirus's tropism to cells of different tissues, improving lentivirus production and titer, etc. The system was optimized. Lentiviruses based on our third-generation lentiviral packaging system can efficiently infect T cells